These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33755735)

  • 1. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
    Pirasteh A; Sorra EA; Marquez H; Sibley RC; Fielding JR; Vij A; Rich NE; Arroyo A; Yopp AC; Khatri G; Singal AG; Yokoo T
    Abdom Radiol (NY); 2021 Aug; 46(8):3708-3716. PubMed ID: 33755735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
    Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
    Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
    Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
    Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
    Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
    Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.
    Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Rowiński O
    Abdom Radiol (NY); 2022 Jan; 47(1):115-122. PubMed ID: 34581927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
    Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
    Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
    Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
    Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma.
    Huh J; Kim B; Lee JH; Won JH; Kim J; Kwon Y; Kim JK
    Invest Radiol; 2021 Feb; 56(2):109-116. PubMed ID: 33405431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes.
    King MJ; Tong A; Dane B; Huang C; Zhan C; Shanbhogue K
    Eur J Radiol; 2020 Dec; 133():109351. PubMed ID: 33096408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 18. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
    Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis.
    Kang JH; Choi SH; Lee JS; Kim KW; Kim SY; Lee SS; Byun JH
    Eur Radiol; 2021 Sep; 31(9):6856-6867. PubMed ID: 33713172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.